simplywall.stAUG 232 min read$CELC

Celcuity (CELC) Losses Widen As Investors Ask If The Bull Case Still Supports Valuation

Celcuity (CELC) reported a wider net loss in Q2 2026, with a 1-month return of 13.21% and a 3-month decline of 32.34%. The company's fair value is estimated at $161.09, significantly higher than its last close at $93.53, based on growth assumptions and potential peak revenue of $2.5b to $3b for its drug gedatolisib. Future trial and regulatory decisions pose risks to this bullish outlook.

Original reporting

simplywall.st

Published Aug 23, 2026, 7:30 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 23, 2026, 9:38 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Celcuity (CELC) Losses Widen As Investors Ask If The Bull Case Still Supports Valuation — source image — Source · simplywall.st

Decision brief

The 30-second read

$CELCNeutralLow

Why it matters

The widened loss underscores cash‑burn concerns, but the long‑term upside remains tied to trial outcomes and market potential.

Market read

Earnings miss may trigger short‑term price pressure; long‑term valuation depends on trial data.

What to watch

Potential partnership or licensing deals could offset the loss impact.

Relevance 5/10Novelty 5/10Timing: post‑quarter earnings release

Background

Celcuity is a clinical‑stage biotech developing gedatolisib for advanced breast and prostate cancers.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CELCNeutralMedium confidence

Context

Q2 2026 results show a wider net loss and mixed share price performance, impacting valuation assessments.

Expected impact

Potential modest downside until trial data updates.

Evidence & confidence

Loss widening is a negative catalyst, but the company’s long‑term valuation hinges on future trial results, limiting immediate trade conviction.

Market effects

Sector

Highlights valuation pressure on clinical‑stage biotech firms awaiting trial data.

Regional

Limited to US biotech investors.

Global

Modest, as the story is company‑specific.

Counterpoint

What could challenge this read

The stock may be undervalued if trial milestones are achieved, offering a long‑term buy opportunity.

Key entities

Company
Celcuity
Clinical‑stage biotech focused on oncology.

Read at source ← All news

SEP 1

$CELCHighAI 8/10

How Investors May Respond To Celcuity (CELC) sNDA For REVTORPYK In PIK3CA-Mutant Breast Cancer

Celcuity Inc. (CELC) submitted an sNDA for REVTORPYK (gedatolisib) to treat HR+/HER2- advanced breast cancer with PIK3CA mutations, based on positive Phase 3 trial data. If approved, it would be the first therapy targeting all class I PI3K isoforms and both mTOR complexes. The company projects $817.9M revenue and $267.5M earnings by 2029, up from current losses. The sNDA builds on the July 2026 approval for non-mutant cases, potentially expanding market reach.

simplywall.st2 min

AUG 30

$CELCMedAI 8/10

What Could Celcuity (CELC) Gain If The FDA Clears REVTORPYK For Breast Cancer?

Celcuity (CELC) submitted a supplemental New Drug Application to the FDA for REVTORPYK to treat advanced breast cancer with PIK3CA mutations. The filing is supported by Phase 3 trial results showing improved progression-free survival. If approved, REVTORPYK could become the first therapy for this indication, potentially expanding Celcuity's market. Management estimates a US$5b to US$6b addressable market and potential peak revenue of US$2.5b to US$3b for gedatolisib in this setting.

simplywall.st2 min

AUG 26

$CELCMedAI 8/10

Celcuity Submits SNDA To FDA For REVTORPYK In Advanced Breast Cancer

Celcuity Inc. (CELC) submitted a supplemental New Drug Application to the FDA for REVTORPYK, an investigational therapy for advanced breast cancer with a PIK3CA mutation. The application is supported by Phase 3 trial data showing significant improvements in progression-free survival and response rates. If approved, REVTORPYK would be the first therapy of its kind for this patient population. CELC stock closed at $92.27, up 1.63%.

rttnews.com1 min

AUG 24

$CELCLow

How Investors May Respond To Celcuity (CELC) Deepening Losses As Gedatolisib Commercial Plans Advance

Celcuity Inc. (CELC) reported a net loss of $78.86 million in Q2 2026, with first-half losses widening to $131.71 million. The company is advancing gedatolisib and preparing for commercialization, with FDA approval of REVTORPYK in July. Investors focus on whether REVTORPYK revenue can offset increased cash burn. Celcuity projects $817.9 million revenue and $267.5 million earnings by 2029, implying a 77% upside from current prices.

simplywall.st3 min

AUG 21

$CELCHighAI 8/10

CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff?

Celcuity Inc. (CELC) shares fell 26% after reporting trial results for gedatolisib in advanced breast cancer. The drug showed reduced disease progression but had treatment-related deaths. The company plans FDA filings based on these results and an upcoming decision in July.

stocktwits.com2 min

AUG 20

$CELCMed

Celcuity (CELC) Q2 2026 Earnings Call Transcript

Celcuity (CELC) reported Q2 2026 net loss of $78.9M ($1.44/ share), up from $45.3M last year. Cash reserves total $754M, with $557.2M raised from a convertible note offering. The company launched Revtopik, a drug for advanced breast cancer, and plans a supplemental New Drug Application. Clinical trials showed significant reduction in disease progression risk. Management expects cash to fund operations into 2029.

fool.com3 min